Esperion Therapeutics Inc
Statements
Cash Flow
Esperion Therapeutics Inc (ESPR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -28 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 16 | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.3 | -14 | -16 | -34 | -26 | -36 | -35 | -43 | -39 | -38 | -29 | 92 | -54 | -58 | -50 | -69 | 139 | -87 | -69 | -89 | -48 | -69 | -58 | -39 | -51 | -43 | -42 | -54 | -25 | -19 | -37 | 54 | -7.2 | -35 | -35 | -23 | -31 | -4.3 | 45 | -28 | -18 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.4 | 0.0 | -0.4 | 0.0 | 0.7 | 0.0 | 0.0 | 1.4 | 0.0 | 1.5 | |
| 4.1 | 3.7 | 3.6 | 4.2 | 5.0 | 4.9 | 4.5 | 5.9 | 5.7 | 5.5 | 6.8 | 6.6 | 6.6 | 6.3 | 6.4 | 7.1 | 7.4 | 7.3 | 6.7 | 5.8 | 8.6 | 5.5 | 4.5 | 4.4 | 3.5 | 3.5 | 3.7 | 2.9 | 3.2 | 3.0 | 2.9 | 3.2 | 2.9 | 3.0 | 2.8 | 2.5 | 2.7 | 2.3 | 2.4 | 2.5 | 9.9 | |
| 4.1 | 3.7 | 3.6 | 4.2 | 5.0 | 4.9 | 4.5 | 5.9 | 5.7 | 5.5 | 6.8 | 6.6 | 6.6 | 6.3 | 6.4 | 7.1 | 7.4 | 7.3 | 6.7 | 5.8 | 17 | 16 | 1.8 | 4.4 | 3.5 | 3.5 | 3.7 | 2.9 | 3.2 | 15 | – | – | – | – | – | – | – | – | – | – | – | |
| 2.3 | -1.0 | 8.8 | 1.9 | 12 | 4.3 | -1.6 | -3.1 | 0.8 | 6.9 | 25 | -2.3 | -6.4 | 0.0 | 1.4 | -2.4 | 2.6 | -14 | 9.0 | -9.4 | -21 | -16 | -5.6 | 1.6 | 0.3 | -3.0 | -2.2 | -7.0 | 10 | 6.6 | 4.0 | -22 | -5.0 | -12 | -21 | 12 | -26 | 21 | -21 | -1.1 | -28 | |
| 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.2 | 0.4 | 0.2 | 0.2 | 0.6 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.4 | |
| 19 | 13 | 7.8 | 16 | 27 | -128 | 48 | 30 | 32 | 40 | 39 | 46 | 27 | -5.3 | -2.9 | 27 | 5.1 | 2.3 | -13 | -50 | -50 | -50 | -50 | -18 | 5.0 | 33 | -12 | 25 | 18 | – | – | -0.1 | -0.1 | -0.2 | – | – | – | – | 0.2 | -0.2 | – | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | |
| 0.0 | 0.0 | 0.0 | 0.3 | 0.1 | 164 | 0.4 | 9.7 | 1.6 | 0.0 | 0.3 | 1.7 | 1.9 | 1.2 | 7.0 | 1.0 | 3.7 | 1.6 | -55 | 2.7 | 0.2 | 4.8 | 215 | – | 20 | 49 | 22 | 53 | -48 | 0.0 | 0.0 | – | -344 | 344 | – | – | – | – | – | – | – | |
| -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.5 | -0.2 | -1.0 | – | – | – | – | 280 | 280 | 280 | 226 | -0.1 | -0.4 | – | – | -0.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.4 | -0.4 | -0.4 | -0.2 | -0.4 | 164 | -0.1 | 9.3 | 1.2 | -0.1 | 0.3 | 1.7 | 127 | 1.0 | 7.0 | 26 | 3.7 | 1.6 | 170 | 2.0 | 49 | 3.7 | 213 | -1.4 | 18 | 47 | -31 | 49 | 0.8 | -4.3 | 4.5 | 91 | -30 | -9.1 | 35 | -7.5 | 2.9 | 11 | 30 | 16 | 60 | |
| 12 | -1.6 | -9.0 | -18 | 0.5 | 0.7 | 13 | -3.6 | -6.4 | 2.4 | 10 | 139 | 99 | -62 | -46 | -17 | 148 | -83 | 89 | -87 | 1.2 | -66 | 105 | -59 | -27 | 36 | -35 | 20 | -6.4 | -24 | -33 | 144 | -37 | -45 | 0.0 | -30 | -29 | 6.4 | 75 | -12 | 42 | |
| -7.3 | -14 | -16 | -34 | -26 | -36 | -35 | -43 | -39 | -38 | -29 | 92 | -54 | -58 | -50 | -70 | 139 | -87 | -69 | -89 | -48 | -69 | -58 | -39 | -51 | -43 | -42 | -54 | -25 | -19 | -37 | 54 | -7.3 | -35 | -35 | -23 | -31 | -4.3 | 45 | -28 | -18 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.